PGP and cancer: Despite this MDR-reversing activity in various cancers, an early report showed the cross-resistance to CD437 (a synthetic RARγ-selective agonist; figure 1) in paclitaxel-resistant human ovarian cancer cells which are overexpressing P-gp [77].